Title: RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS Document date: 2018_12_19
ID: r79h9yzz_852
Snippet: No significant difference was found for all analysed parameters between the three groups. Adverse effects were frequently observed and included gastrointestinal signs, cytopenias, facial excoriations, and increase in liver enzymes. In the Felimazole® group 31.2%, in the Vidalta® group 40.0%, and in the CHM group 28.6% of treated cats developed adverse effects. Median survival times were 540 days in the Felimazole® , 365 days in the Vidalta® ,.....
Document: No significant difference was found for all analysed parameters between the three groups. Adverse effects were frequently observed and included gastrointestinal signs, cytopenias, facial excoriations, and increase in liver enzymes. In the Felimazole® group 31.2%, in the Vidalta® group 40.0%, and in the CHM group 28.6% of treated cats developed adverse effects. Median survival times were 540 days in the Felimazole® , 365 days in the Vidalta® , and 524 days in the CHM group. The only parameter influencing survival time was presence of chronic renal disease (CRD) prior to therapy. Those cats had a significantly shorter survival time (203.5 days) compared to cats in which CRD occurred during therapy (619 days) and cats without CRD (396 days).
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date